Investment Thesis
Oragenics is in severe financial distress with revenue collapsed 71% YoY to $37.7K while burning $2.3M annually in operating losses. Despite $6.1M in cash reserves and zero debt, the company demonstrates fundamental business model failure evidenced by zero gross profit and negative cash flows. Current cash runway provides only ~2.6 years before insolvency at present burn rate.
Strengths
- Zero debt and strong balance sheet with $6.1M cash reserves providing near-term solvency
- Excellent liquidity with 4.17x current ratio and no long-term obligations
- Current financial position allows time for potential strategic pivots or asset sales
Risks
- Catastrophic revenue collapse of 71.4% YoY to near-zero levels ($37.7K)
- Massive operating losses with negative margins exceeding -5000% indicating fundamental business failure
- Negative operating cash flow of -$2.2M and free cash flow of -$2.3M demonstrates unsustainable burn rate
- Zero gross profit indicates inability to monetize core operations or generate scalable revenue
- Limited cash runway of approximately 2.6 years at current burn rate before capital exhaustion
- No insider activity in 90 days suggests management lacks confidence in turnaround prospects
Key Metrics to Watch
- Operating cash flow trend and monthly cash burn rate
- Revenue growth and gross margin recovery as primary turnaround indicators
- Cash balance depletion timeline and liquidity adequacy
Financial Metrics
Revenue
37.7K
Net Income
-2.2M
EPS (Diluted)
$-0.51
Free Cash Flow
-2.3M
Total Assets
7.5M
Cash
6.1M
Profitability Ratios
Gross Margin
0.0%
Operating Margin
-5,991.4%
Net Margin
-5,846.1%
ROE
-35.6%
ROA
-29.4%
FCF Margin
-6,183.2%
Balance Sheet & Liquidity
Current Ratio
4.17x
Quick Ratio
4.17x
Debt/Equity
0.00x
Debt/Assets
17.5%
Interest Coverage
-318.41x
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-10T07:40:16.158518 |
Data as of: 2026-03-31 |
Powered by Claude AI